In the new edition of its biosimilars leaflet, he Drug Commission of the German Medical Association (AkdÄ) informs on the use and the safety profile of biosimilars. Additionally, the Drug Commission points out important aspects of market authorisation and special requirements for pharmacovigilance as well as the interchangeability of reference drugs and biosimilars. So far, 52 biosimilars for 16 different agents are available in Germany. Furthermore, the guideline was extended by information on biosimilars in oncology.
Comments are closed.